Gut microbiota and gut-derived metabolites in defining multiple sclerosis phenotypic continuum
-
By
-
Federico Montini
-
Ashutosh Mangalam
-
Burcu Zeydan
-
Joseph Murray
-
Orhun H. Kantarci
-
July 1, 2026
-
Clinical Scorecard: The Role of Gut Microbiome and Its Metabolites in Characterizing the Phenotypic Spectrum of Multiple Sclerosis
At a Glance
| Category | Detail |
|---|
| Condition | Multiple Sclerosis |
| Key Mechanisms | Alterations in gut microbiome linked to immune dysregulation, barrier dysfunction, neuroinflammation, and demyelination. |
| Target Population | Individuals with Multiple Sclerosis |
| Care Setting | Research and clinical settings focusing on gut-immune-brain interactions. |
Key Highlights
- Microbial metabolites influence T-cell differentiation and neuroimmune communication.
- Longitudinal studies show associations between metabolite profiles and disability worsening.
- Microbial metabolism can be reshaped by disease-modifying therapies and diet.
Guideline-Based Recommendations
Diagnosis
- Identify alterations in gut microbiome composition in MS patients.
Management
- Consider microbiome-directed interventions as potential therapeutic targets.
Monitoring & Follow-up
- Assess microbial metabolic profiles in relation to disease progression.
Risks
- Acute infections may impact inflammatory-demyelinating biology in MS.
Patient & Prescribing Data
Patients diagnosed with Multiple Sclerosis.
Microbial metabolites may represent promising therapeutic targets.
Clinical Best Practices
- Integrate microbiome research into clinical practice for precision therapies.
- Focus on understanding microbial metabolism and host interactions.
Related Resources & Content
